C3 Selected as Platinum Member of the National Organization for Rare Diseases

Coalition to Cure Calpain 3 (C3) has joined the National Organization for Rare Diseases (NORD) as a Platinum Member. This level of membership represents the highest level of integrity and transparency for patient advocacy organizations involved in medical research, drug development, medical education, and registries.

NORD is an independent advocacy organization representing the approximately 25-30 million Americans affected by a rare disease. NORD has led the way in voicing the needs of the rare disease community, driving supportive policies and education, and advancing medical research. Over 300 disease-specific patient organizations are NORD Member Organizations.

As a Platinum Member of NORD, C3 will benefit from NORD’s established presence as an advocate for the rare disease community. NORD provides a wealth of resources related to best practices for rare disease patient groups and helps member organizations promote their programs.

“C3 is pleased to be approved as a Platinum NORD member organization,” says Dr. Jennifer Levy, C3 Scientific Director. “We look forward to working closely with NORD to represent the needs of people living with rare diseases including LGMD2A/R1.”

Recent Posts

  • New Research Grant Aims to Improve Understanding of Dominant Calpainopathy

    C3 is pleased to share that a research grant has been awarded to Drs. Ana Töpf, Jordi Diaz-Manera, and Volker Straub at the John Walton Muscular Dystrophy Research Centre at Newcastle University. This project, titled “Understanding the variable expression of dominant calpainopathies,” explores the molecular basis for LGMDD4, also known as dominant calpainopathy. The Challenges... Read More
  • Dr. Melissa Spencer provides update on development of an LGMD2A/R1 gene therapy

    Melissa Spencer, PhD, Chair of the C3 Scientific Advisory Board and Professor of Neurology at UCLA, recently presented during a webinar hosted by the Muscular Dystrophy Association (MDA). The presentation, aimed at educating the public, gave an excellent background about genes, mutations, and adeno-associated vector (AAV)-based gene therapies. She highlights some of the latest advances... Read More